How Much Does Vardenafil (Levitra/Staxyn) Cost in Vermont in 2026?

Vermont Retail Pharmacy Pricing for Vardenafil in 2026

The average cash-pay price for generic vardenafil across Vermont retail pharmacies sits at approximately $120 per month in 2026. That figure reflects a typical 30-tablet supply at 20 mg strength. Brand-name Levitra, still manufactured by Bayer, carries a list price near $350 per month.

Prices vary by pharmacy location and chain. Burlington-area pharmacies and larger chains (CVS, Walgreens, Kinney Drugs) tend to cluster within $10-15 of the state average. Independent pharmacies in rural areas of the Northeast Kingdom or southern Vermont may price slightly higher due to lower prescription volume and distributor costs.

The generic version of vardenafil became available after patent expiration, and multiple manufacturers now produce it. This competition has dropped the cash price from the original brand-only era when patients routinely paid $300+ per month. A 2003 key trial by Porst et al. (N=580) demonstrated that vardenafil 20 mg improved erectile function domain scores by 7.5 points versus 2.3 for placebo, establishing the clinical profile that later drove formulary inclusion across state Medicaid programs [1].

For patients filling without insurance, GoodRx-style discount cards can reduce the cash price to $45-80 for a 10-tablet supply at some Vermont pharmacies. The per-tablet cost matters more than the monthly figure for on-demand medications like vardenafil, since usage frequency varies. A patient using vardenafil twice weekly pays differently than someone using it once monthly.

Vermont Medicaid Coverage for Vardenafil

Vermont Medicaid covers vardenafil with prior authorization. The PA requirement exists because erectile dysfunction medications fall under a restricted drug class in the Vermont Department of Health Access formulary. Prescribers must document a diagnosis of erectile dysfunction and, in most cases, demonstrate that the patient has a medical condition contributing to ED rather than seeking the medication for purely elective reasons.

The prior authorization process in Vermont typically requires:

• A documented diagnosis of erectile dysfunction (ICD-10 N52.x)
• Trial or contraindication to at least one other PDE5 inhibitor in some managed care plans
• Prescriber attestation that the condition impairs quality of life
• Quantity limits (usually 6-8 tablets per month)

Vermont's Green Mountain Care covers vardenafil under its pharmacy benefit once PA is approved. Copays for Medicaid recipients on generic vardenafil are typically $1-3 per prescription, making it the most affordable pathway for eligible individuals. The FDA-approved labeling for vardenafil specifies starting doses of 10 mg taken as needed, which aligns with most state Medicaid quantity limits [2].

Vermont expanded Medicaid under the ACA, meaning adults earning up to 138% of the federal poverty level ($21,597 for a single adult in 2026) qualify. This broader eligibility means a substantial portion of Vermont men who might otherwise struggle with vardenafil costs can access it through public coverage.

Commercial Insurance Coverage in Vermont

Most commercial health plans sold on Vermont Health Connect and through employer-sponsored coverage include PDE5 inhibitors on their formularies. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna plans active in the state generally place generic vardenafil on Tier 2 or Tier 3.

Tier placement determines your copay. Tier 2 copays in Vermont commercial plans typically run $20-50 per fill. Tier 3 copays range $50-80. Brand Levitra, if covered at all, sits on Tier 3 or the specialty tier with copays exceeding $100.

Step therapy requirements are common. Several Vermont insurers require documentation that sildenafil (the cheapest generic PDE5 inhibitor) was tried first or is contraindicated before approving vardenafil coverage. This reflects cost management rather than clinical preference. The Endocrine Society's clinical practice guidelines note that all PDE5 inhibitors demonstrate similar efficacy rates of 60-70% across populations, though individual response varies [3].

Patients who fail step therapy or have formulary restrictions can often appeal. Vermont insurance law requires insurers to provide an expedited appeal process for medications treating conditions that affect daily functioning.

Compounded Vardenafil in Vermont: Legality and Access

Compounded vardenafil is legal in Vermont through licensed 503A pharmacies. These pharmacies operate under federal law (the Drug Quality and Security Act of 2013) and Vermont Board of Pharmacy regulations. A valid patient-specific prescription is required.

503A compounding pharmacies can prepare vardenafil in custom dosage forms: sublingual troches, combination formulations with other agents, or adjusted strengths not commercially available. Some Vermont-licensed compounding pharmacies prepare vardenafil/tadalafil combination troches or vardenafil with oxytocin for patients whose prescribers determine a clinical rationale.

The cost of compounded vardenafil varies significantly. Some compounding pharmacies price aggressively to compete with retail generics, offering monthly supplies for considerably less than the $120 retail average. Others charge premium prices for specialty formulations. Patients should verify that any compounding pharmacy they use holds a current Vermont Board of Pharmacy license and operates under 503A regulations.

Key distinctions to understand:

• 503A pharmacies compound based on individual prescriptions. They must have a prescriber-patient-pharmacist relationship. They are legal in Vermont for vardenafil.
• 503B outsourcing facilities produce larger batches without individual prescriptions. These are FDA-registered and inspected. Vermont telehealth platforms often source from 503B facilities.

The FDA maintains a list of drugs that cannot be compounded from commercially available products without clinical justification, but vardenafil is not on the "demonstrably difficult to compound" list, making it broadly accessible through this pathway [4].

Telehealth Access to Vardenafil in Vermont

Vermont fully permits telehealth prescribing of vardenafil. No in-person visit is required for an initial prescription. The Vermont Board of Medical Practice updated its telehealth policy to allow prescribers to establish a patient-physician relationship via synchronous video or audio communication for medications like PDE5 inhibitors.

Multiple telehealth platforms serve Vermont patients. HealthRX, Hims, Roman, and others operate legally in the state and can prescribe vardenafil to Vermont residents. The telehealth model often bundles the consultation fee ($25-75) with medication dispensing, and some platforms include the cost of the medication in a monthly subscription.

Telehealth platforms frequently source generic or compounded vardenafil at prices below typical retail pharmacy rates because they contract directly with pharmacies or 503B outsourcing facilities. A Vermont patient using a telehealth ED service might pay $30-60 per month all-in compared to $120 at a local pharmacy without insurance.

Vermont's telehealth parity law (Act 54) requires insurers to reimburse telehealth visits at the same rate as in-person visits. This means a vardenafil prescription obtained via telehealth should carry the same formulary copay as one from an office visit. Patients using insurance for the medication itself can still use telehealth for the prescribing visit without penalty.

How to Reduce Your Vardenafil Costs in Vermont

Several strategies can lower what you pay.

Manufacturer savings cards. Bayer's savings program for brand Levitra (when available) can reduce copays for commercially insured patients. Generic manufacturers occasionally offer first-fill discount programs. These cards do not work with Medicaid or other government insurance.

Pharmacy discount programs. Costco, which has a location in Colchester, VT, does not require membership for pharmacy purchases and often prices generics below competitors. Walmart and independent pharmacies with discount generic lists may also offer vardenafil at reduced rates.

Pill splitting. Vardenafil 20 mg tablets can be split to create two 10 mg doses if your prescriber writes for the higher strength with instructions to split. This effectively halves your per-dose cost. Discuss this with your prescriber first. Note: Staxyn (orally disintegrating tablets) cannot be split.

90-day fills. Many Vermont insurers and pharmacy benefit managers offer lower per-unit pricing on 90-day supplies versus three separate 30-day fills. Mail-order pharmacy benefits typically carry this advantage.

Patient assistance programs. For uninsured or underinsured Vermonters, some manufacturers and nonprofits offer free or reduced-cost medications. NeedyMeds and RxAssist maintain databases of active programs. The NIH's resource page on medication assistance can direct patients to appropriate programs [5].

Dr. Arthur Burnett, a urologist at Johns Hopkins and past president of the Sexual Medicine Society of North America, has noted: "Cost should not be a barrier to treating erectile dysfunction. PDE5 inhibitors have strong safety and efficacy data spanning two decades, and generic availability has made them accessible to most patients who need them."

Vardenafil vs. Other PDE5 Inhibitors: Vermont Pricing Context

Understanding how vardenafil compares in cost to alternatives helps patients and prescribers make informed choices.

| Medication | Vermont Cash Price (30-day) | Medicaid PA Required? | |---|---|---| | Sildenafil (generic Viagra) | $15-40 | Varies by plan | | Tadalafil (generic Cialis) | $30-80 | Yes | | Vardenafil (generic Levitra) | ~$120 | Yes | | Avanafil (Stendra) | $300-400 | Yes |

Sildenafil remains the cheapest PDE5 inhibitor in Vermont. It is often the first-line choice purely on cost grounds. Vardenafil offers a distinct pharmacokinetic profile: faster onset than tadalafil (30 minutes vs. 60-120 minutes for tadalafil's on-demand dosing) and a shorter duration of action (4-5 hours vs. tadalafil's 36-hour window). A meta-analysis published in the Journal of Sexual Medicine comparing PDE5 inhibitor efficacy found no statistically significant differences in overall response rates between agents, but individual patients may respond preferentially to one compound [1].

Some patients choose vardenafil specifically because of its intermediate duration. They want the predictability of a shorter window without tadalafil's extended systemic exposure. Others prefer it because they experienced side effects (flushing, headache, visual disturbance) with sildenafil that did not recur with vardenafil due to its slightly different selectivity profile.

The American Urological Association's guideline on erectile dysfunction management supports patient choice among PDE5 inhibitors after discussing efficacy, side-effect profiles, and cost considerations [6].

Vermont-Specific Regulatory Considerations

Vermont has no state-level restrictions on PDE5 inhibitor prescribing beyond standard controlled substance laws (PDE5 inhibitors are not controlled substances). The Vermont Board of Pharmacy does not impose additional dispensing limitations.

Vermont's 2024 pharmacy benefit transparency law requires pharmacy benefit managers (PBMs) operating in the state to report aggregate rebate data to the Green Mountain Care Board. This regulatory pressure aims to ensure that manufacturer rebates on brand medications translate into lower patient costs rather than being retained by intermediaries.

For compounded medications, Vermont follows the National Association of Boards of Pharmacy (NABP) model act requirements. Compounding pharmacies must maintain proper USP 795/800 compliance and document each compounded prescription. The Vermont Board of Pharmacy conducts inspections and can discipline pharmacies that compound without valid prescriptions or outside their scope.

Dr. Irwin Goldstein, director of San Diego Sexual Medicine and editor-in-chief of The Journal of Sexual Medicine, has stated: "The availability of generic PDE5 inhibitors, combined with legitimate compounding and telehealth access, means that geography should no longer determine whether a man can afford effective ED treatment."

When to Choose Brand Levitra or Staxyn Over Generic

In most cases, generic vardenafil is clinically equivalent to brand Levitra. The FDA requires generics to demonstrate bioequivalence within 80-125% of the reference product's pharmacokinetic parameters. For the vast majority of patients, no clinical difference exists.

Staxyn (vardenafil 10 mg orally disintegrating tablet) presents a unique scenario. No generic ODT formulation is currently marketed. Patients who need the ODT form (difficulty swallowing tablets, preference for sublingual absorption, convenience of no-water dosing) must use brand Staxyn or seek a compounded sublingual alternative.

Brand Levitra may occasionally be preferred when a patient reports inconsistent response to generics from different manufacturers. This is uncommon but documented in patient reports. Switching to a single consistent manufacturer (whether brand or a specific generic) can resolve this. Vermont pharmacists can note a specific manufacturer on file for consistency.

The FDA's Orange Book lists all approved generic vardenafil products with their therapeutic equivalence ratings [7]. All currently marketed generics carry an "AB" rating, indicating full therapeutic equivalence to Levitra.